Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Avadel Pharmaceuticals PLC
Operating Income
Avadel Pharmaceuticals PLC
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Operating Income
-$148.7m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-9%
|
|
Perrigo Company PLC
NYSE:PRGO
|
Operating Income
$221.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-10%
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Operating Income
$518.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
10%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Operating Income
-$41.2m
|
CAGR 3-Years
-351%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Operating Income
€12.2m
|
CAGR 3-Years
61%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Ovoca Bio PLC
LSE:OVB
|
Operating Income
-€2.3m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
12%
|
See Also
What is Avadel Pharmaceuticals PLC's Operating Income?
Operating Income
-148.7m
USD
Based on the financial report for Mar 31, 2024, Avadel Pharmaceuticals PLC's Operating Income amounts to -148.7m USD.
What is Avadel Pharmaceuticals PLC's Operating Income growth rate?
Operating Income CAGR 10Y
-9%
Over the last year, the Operating Income growth was -51%. The average annual Operating Income growth rates for Avadel Pharmaceuticals PLC have been -45% over the past three years , -36% over the past five years , and -9% over the past ten years .